novo nordisk glp-1 receptor agonist weight management diabetes treatments New loss drugs are about to ship to more American homes Interdependence-Aware Attribution in Real-World Evidence:

10.1056/NEJMoa2404881 [DOI] [PMC free article] [PubMed] [Google Scholar] 50.Blackman A, Foster GD, Zammit G, Rosenberg R, Aronne L, Wadden T, et al

[DOI] [PubMed] [Google Scholar] 145.Ligumsky H., et al

Bitter melon extracts and some other herbal preparations have shown promising GLP1like effects in animals and small human studies

From a mechanistic standpoint, this dual action explains why the same class can be used for both diabetes and weight management

But after giving it a full 60-day try, I can honestly say Im amazed

Drug Class Analysis GLP-1 Weight Loss Drug Market by Drug Class: Injectable and Dual Agonist Therapies Command 78.4% of Revenue Drug Class Revenue Share, CAGR, and Commercial Drivers GLP-1 Obesity Drug Market 2026 Injectable GLP-1 receptor agonist monoagonists hold a 32.8% GLP-1 market revenue share in 2026 , reflecting Wegovys position as the most commercially successful weight management drug in pharmaceutical history